PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?

background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. however, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC). the aim of this work is to assess the clinical value of PSMA ligand PET/CT in patients with CRPC. results: PSMA ligand PET has demonstrated higher detection rates in comparison to conventional imaging and allows for a significant reduction in the number of M0 CRPC patients. however, its real impact on patients' prognosis is still an open question. moreover, in CRPC patients, PSMA ligand PET presents some sensitivity and specificity limitations. due to its heterogeneity, CRPC may present a mosaic of neoplastic clones, some of which could be PSMA-/FDG+, or vice versa. likewise, unspecific bone uptake (UBU) and second primary neoplasms (SNPs) overexpressing PSMA in the neoangiogenic vessels represent potential specificity issues. Integrated multi-tracer imaging (PSMA ligand and [18F]FDG PET) together with a multidisciplinary discussion could allow for reaching the most accurate evaluation of each patient from a precision medicine point of view.